

Alternative Financing Solutions for Emerging Biopharma Companies

Discuss, Develop and Finance Your Next Clinical Inflection Point

- Utilize Your Publicly Traded Stock to Structure "Payment-in-Kind Services"
- Structure R&D/Pipeline Development in "M&A Transactions" to Create a 'Win-Win' Pathway
- How to Create a Capital Efficient Proof-of-Concept Clinical Trial
- Non-Dilutive Pathways of Financing for Public and Private Companies: SBIR and DOD Grants, NIH Funding, etc.

Presenters:

Michael A. Recny, Ph.D. - CEO - Calvert Holdings, Inc.

To discuss an equity investment company that structures pre-clinical services for equity deals.

Rich Shea, MBA- CEO - Vascular Pharmaceuticals

To discuss experience in raising capital with a specific focus on partnering with large pharma to accomplish clinical goals of a small biotech.

Bill Wilkison, PhD - CSO - BHV Pharma

To discuss experience in raising capital: Do's and Don'ts along with partnering with international pharma to accomplish clinical goals of a small biotech.

Mike Loftus- Executive Director- Integrium

Erich McGilvrey - Senior Director - Integrium

To discuss the 4 keys to a PoC Trial in addition to services for equity on a Phase Ib-IIa transactions.



December 15th

8AM - 11AM

Breakfast served

North Carolina
Biotechnology Center

15 T.W. Alexander Drive
Research Triangle Park, NC

Please register for the event with Erich McGilvrey

(919) 924-6081 | emcgilvrey@integrium.com

